Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

-Amended Agreement Accelerates Expected Timing of Final Analysis by One Year While Maintaining Comparable Powering of Interim and Final Results- -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM

ET-

SEATTLE, March 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has agreed to an amended Special Protocol Assessment (SPA) for the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. In addition, the FDA has reconfirmed that they would accept a positive interim or final analysis from the IMPACT trial to amend the Biologics License Application (BLA) for licensure of PROVENGE.

The amended SPA accelerates the expected timing of the final IMPACT results by approximately one year while maintaining comparable powering of the study's interim and final results. By increasing the number of events and decreasing the alpha (false positive error) spending function for the interim analysis, the Company is able to reduce the number of events for the final analysis (from 360 to 304) and still maintain a comparable statistical power for both the interim and final analyses. Interim results are still expected in the second half of 2008; however, final results are now expected in the second half of 2009 rather than 2010.

Based on the statistical plan in the amended SPA, if the treatment effect at the interim analysis for the IMPACT trial is consistent with the integrated results of the previous two completed pha
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/18/2014)... 18, 2014 The Asia-Pacific Bio-based ... segments the bio-based advanced phase change material market ... , Browse through the TOC of the Asia-Pacific ... get an idea of the in-depth analysis provided. ... in the Asia-Pacific bio-based advanced phase change material ...
(Date:10/18/2014)... Asia-Pacific Liquid Crystal on Silicon (LCoS) display market report ... analysis and forecast of revenue. This market was valued ... reach $380.0 million by 2018, at a CAGR of ... TOC of the Asia-Pacific LCoS display market report, to ... also provides a glimpse of the segmentation of the ...
(Date:10/18/2014)... The report " Cloud Analytics Market [Cloud ... Machine; Video; Predictive Analytics: Global Advancements, Delivery Models, ... (2013 - 2018) ", defines and segments the ... with an in-depth analysis and forecasting of market ... this market, various restraints, and opportunities impacting it ...
(Date:10/17/2014)... DIEGO and HILDEN, Germany ...   , Translational research in ... capabilities being presented at the American Society of ... of 250,000-plus DNA samples linked to Ingenuity ® ... depth for genomic analysis  Ingenuity ® ...
Breaking Biology Technology:The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 2QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 3QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 4QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 5QIAGEN Demonstrates Expanded Bioinformatics Workflows at ASHG; Strong Market Adoption as Researchers Analyze Genomic Data on More Than a Quarter-Million Samples in Secure Private Cloud 6
... (Nasdaq and SWX: BMRN) announced today the appointment,of ... Former Vice President of,Research and Development for Raven ... patents and the recipient of a,collection of prestigious ... Awards from Intellectual Property Owners, Inc., "We ...
... KNDL ), a,leading, global full-service clinical research ... Candace Kendle, PharmD,will participate in the Wachovia 2008 ... Langham Hotel in Boston, Jan. 29-31, 2008. Kendle,s,presentation ... p.m. Eastern Time., (Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO ...
... Phytomedics Inc., a clinical,stage biopharmaceutical company developing ... it will present at the,Wachovia 2008 Healthcare Conference ... p.m. ET., Among the topics of the ... and business developments, including Phase III development,activities related ...
Cached Biology Technology:BioMarin Appoints Dr. Gordon Vehar, Vice President of Research 2BioMarin Appoints Dr. Gordon Vehar, Vice President of Research 3Kendle to Present at the Wachovia 2008 Healthcare Conference 2
(Date:10/16/2014)... severe respiratory tract infections and worldwide claims the ... VIB and Ghent University have succeeded in developing ... virus infection. , Xavier Saelens (VIB/UGent): "We ... way for the development of a novel approach ... suffering in numerous small children and elderly people." ...
(Date:10/15/2014)... ability to assess the pandemic risk from strains of ... must not allow ourselves to become complacent that the ... consortium of scientists. , Influenza pandemics arise when a ... to develop widespread immunity – spreads in the human ... past 100 years, the worst of which – the ...
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... stomp, curse or ignore insects, says Cornell University entomologist ... dollar value of some of those insect services is ... The research appears in the journal BioScience today (April ... our environment and lives in ways that scientists are ...
... Researchers have discovered the genetic controls which cause trees ... as well as the mechanism that causes them to ... in understanding the basic genetics of tree growth. , ... University of Agricultural Sciences, Oregon State University and two ...
... a potentially powerful new therapy for treating diabetes, peripheral ... tube and into animals by demonstrating it restores nerve ... has particularly important implications for the estimated 21 million ... and blood vessels. , The therapy involves netrins, a ...
Cached Biology News:Value of services performed by insects tops $57 billion in US 2Value of services performed by insects tops $57 billion in US 3Discovery may speed forest biotechnology 2Discovery may speed forest biotechnology 3Proteins spur diabetic mice models to grow blood vessels, nerves 2
... StatMatic I provides a convenient and affordable ... work. Used with an eight-port disposable manifold, ... possible with multi-channel pipettes. The eight-port manifold, ... volumes of 100, 200, 250, or 300mL ...
These 25x25 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick. • Approx. Pcs Oz : 102...
... Science FLA-8000 Fluorescent Image Analyzer features fluorescent ... laser imaging system. This powerful new research ... fluorescent dyes or radioisotopes at resolutions meeting ... Speed, image quality and flexibility make the ...
...
Biology Products: